As of 12:44pm ET
| +0.04 / +1.25%|
Ohr Pharmaceutical, Inc. is focused on the development of novel pharmaceuticals for the treatment of serious and unmet medical needs. The company products include Squalamine eye drops for the treatment of the wet form of age-related macular degeneration (wet AMD) with a potential for expansion into other indications such as diabetic macular edema (DME) and retinal vein occlusions (RVO) and OHR/AVR 118 for the treatment of Cancer Cachexia, or wasting syndrome, is characterized by symptoms of loss of appetite and body weight, fatigue, and loss of muscle mass. Ohr Pharmaceutical was founded in 2008 and is headquartered in New York, NY.
|Jason Scott Slakter||Chief Executive Officer & Director|
|Irach B. Taraporewala||President, Director & Chief Technology Officer|
|Samuel I. Backenroth||Chief Financial Officer & VP-Business Development|
|Glenn Stoller||Chief Scientific Officer|
|Avner Ingerman||Chief Clinical Officer|